Ascentage Pharma Group International – Unsponsored ADR (NASDAQ:AAPG – Get Free Report)’s stock price gapped down before the market opened on Tuesday. The stock had previously closed at $15.45, but opened at $14.69. Ascentage Pharma Group International shares last traded at $14.6120, with a volume of 3,497 shares changing hands.
Wall Street Analyst Weigh In
Several research analysts have recently commented on AAPG shares. JPMorgan Chase & Co. decreased their price objective on Ascentage Pharma Group International from $46.00 to $33.00 and set an “overweight” rating on the stock in a research note on Thursday, October 8th. William Blair assumed coverage on Ascentage Pharma Group International in a research note on Friday, October 16th. They set an “outperform” rating for the company. BTIG Research reissued a “buy” rating and issued a $48.00 target price on shares of Ascentage Pharma Group International in a report on Friday, August 21st. Citigroup began coverage on shares of Ascentage Pharma Group International in a research note on Wednesday, October 14th. They set a “buy” rating and a $46.00 target price on the stock. Finally, Citizens Jmp began coverage on shares of Ascentage Pharma Group International in a report on Tuesday, October 13th. They issued a “market outperform” rating and a $35.00 target price for the company. Two equities research analysts have rated the stock with a Strong Buy rating and twelve have issued a Buy rating to the company. According to MarketBeat.com, the company currently has a consensus rating of “Buy” and a consensus target price of $43.90.
Get Our Latest Analysis on Ascentage Pharma Group International
Ascentage Pharma Group International Stock Performance
The company has a quick ratio of 1.18, a current ratio of 1.22 and a debt-to-equity ratio of 1.09. The stock has a fifty day moving average of $16.17 and a 200 day moving average of $20.53.
Ascentage Pharma Group International (NASDAQ:AAPG – Get Free Report) last released its quarterly earnings data on Wednesday, August 19th. The company reported ($0.65) earnings per share (EPS) for the quarter. The firm had revenue of $22.24 million for the quarter. As a group, equities analysts forecast that Ascentage Pharma Group International – Unsponsored ADR will post -2.43 earnings per share for the current year.
About Ascentage Pharma Group International
Ascentage Pharma Group International is a commercial-stage biopharmaceutical company focused on developing and commercializing treatments for cancer and other serious diseases.
See Also
- Five stocks we like better than Ascentage Pharma Group International
- Analysts Turn Bullish on Meta Platforms Despite Post-Earnings Fall
- Approaching Earnings Season, Are Pure Play Quantum Stocks Still a Good Bet?
- Lockheed Martin’s F-35 Deal Could Change How Wall Street Values the Stock
- Merck and Moderna’s Cancer Vaccine Worked—Who Gets Paid?
Receive News & Ratings for Ascentage Pharma Group International Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ascentage Pharma Group International and related companies with MarketBeat.com's FREE daily email newsletter.
